The riskbenefit percentage may vary coming from case to case however it is important that doctors counsel their individuals so as to tell them of their choices so that they can enhance their medications, ideally prior to conception. It really is hoped that sufficient data will be obtained from registries and studies such as the OTIS Autoimmune Diseases in Pregnancy Project so that in future women and their particular doctors will have better information on which to base important decisions regarding management of RA in pregnancy. == REFERENCES ==. disease-modifying real estate agents to reduce or prevent permanent tissue damage. There is a new class of drugs that can be used to target specific cells and cytokines that have been called biological agents. These drugs have already been shown to significantly reduce inflammation and to retard the progression of joint damage in RA thereby reducing symptoms and increasing function. 2 Keywords: medical pharmacology, drugs (medication), immunology, rheumatology == INTRODUCTION == The biological disease-modifying antirheumatic agents or biologics available for use in Sydney for inflammatory musculoskeletal disorders include real estate agents that prevent tumour necrosis factor alpha dog (TNF-), namely adalimumab (Humira), etanercept (Enbrel) and infliximab (Remicade), the interleukin-1 (IL-1) receptor antagonist anakinra (Kineret), the CTLA4 analogue abatacept (Orencia) and rituximab (Mabthera), which is a monoclonal antibody to CD20 and which reduces B-cell figures. These real estate agents are becoming increasingly used to treat a number of conditions including rheumatoid arthritis (RA), psoriatic joint disease, ankylosing spondylitis as well as non-rheumatic autoimmune illnesses such as Crohn’s disease and psoriasis. The efficacy of such medications in RA is improved when employed in combination with other disease-modifying drugs, particularly methotrexate. In Australia, the Pharmaceutical Benefits Scheme will simply support the use of infliximab, anakinra and rituximab for RA in individuals taking methotrexate. Therefore , individuals are often on a combination of traditional disease-modifying drugs and biologics. A questionnaire was delivered to 600 people of the American College of Rheumatology regarding their belief of fetal risk and MHP 133 the use of birth control for women using disease-modifying antirheumatic drugs, which included infliximab and etanercept as well as leflunomide and methotrexate. In the 175 respondents, 38. 6% and 46. 5% agreed that pregnancy was contraindicated in ladies taking etanercept or infliximab, respectively, in MHP 133 contrast to 95% and 92. 5% for methotrexate and leflunomide, respectively. Accordingly they recommended birth control MHP 133 in 75% of women taking etanercept and MHP 133 MHP 133 73. 4% of women taking infliximab (compared with over 95% for leflunomide and methotrexate). Two pregnancies were exposed to infliximab and 15 to etanercept, including one who was also exposed to methotrexate. There have been no anomalies reported in the babies exposed to infliximab or etanercept. several It is important to note that much in the data with regards to exposures to these medications is usually difficult to interpret for a number of reasons: the actual quantity of exposed pregnancies is small; the women possess often severe underlying medical conditions that in and of themselves may lead to poor pregnancy outcomes; many of the women take multiple medications some of which are known teratogens, such as methotrexate; and the ascertainment and timing of the exposures is often problematic (for example pregnancies notified restrospectively to drug companies may be biased towards unfavorable outcomes and exact timing of the direct exposure in relation to gestation is often inaccurate). Given that each one of these agents are new and that relatively few women take these medications during pregnancy, there is certainly extremely limited data available about their protection in individual pregnancy with regards to infant end CRF (human, rat) Acetate result and risks of main birth defects as well as other adverse pregnancy outcomes. Even less is known about potential long-term sequelae (if any) of these real estate agents such as effects on growth or within the developing defense mechanisms. Due to the paucity of data available about the safety of this number of drugs in human pregnancy, the Organization of Teratology Info Specialists (OTIS) established an Autoimmune Illnesses in Pregnancy Project to study not only the course of autoimmune diseases during pregnancy, but also the effects of the biological real estate agents (predominantly adalimumab) on pregnancy and baby outcome. 4 Other registries have also been established to address queries regarding the protection of these real estate agents in pregnancy. In the United Kingdom, almost all patients commenced on a biologic for joint disease must be joined onto the British.